REFERENCES
1. Lugari S, Baldelli E, Lonardo A. Metabolic primary liver cancer in adults: risk factors and pathogenic mechanisms. Metab Target Organ Damage. 2023;3:5.
2. Wu C, Targher G, Byrne CD, et al. Global, regional, and national burden of primary liver cancer attributable to metabolic risks: an analysis of the Global Burden of Disease Study 1990-2021. Am J Gastroenterol. 2025;120:2280-90.
3. Weiskirchen R, Lonardo A. Obesity, metabolic dysfunction-associated steatotic liver disease and hepatocellular carcinoma: how molecular changes impact cellular functions. BIOCELL. 2026;50:1-10.
4. Llovet JM, Ricci S, Mazzaferro V, et al. ; SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359:378-90.
5. Kudo M, Finn RS, Qin S, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018;391:1163-73.
6. Finn RS, Qin S, Ikeda M, et al. ; IMbrave150 Investigators. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020;382:1894-905.
7. Abou-Alfa GK, Lau G, Kudo M, et al. Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma. NEJM Evid. 2022;1:EVIDoa2100070.
10. European Association for the Study of the Liver. EASL Clinical Practice Guidelines on the management of hepatocellular carcinoma. J Hepatol. 2025;82:315-74.
11. Reig M, Sanduzzi-Zamparelli M, Forner A, et al. BCLC strategy for prognosis prediction and treatment recommendations: the 2026 update. J Hepatol. 2026;84:631-54.
12. de Franchis R, Bosch J, Garcia-Tsao G, Reiberger T, Ripoll C. ; Baveno VII Faculty. Baveno VII - renewing consensus in portal hypertension. J Hepatol. 2022;76:959-74.
